MARKET

URGN

URGN

Urogen Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.41
-0.17
-0.83%
After Hours: 20.41 0 0.00% 16:51 11/23 EST
OPEN
21.35
PREV CLOSE
20.58
HIGH
21.35
LOW
20.20
VOLUME
89.26K
TURNOVER
--
52 WEEK HIGH
35.21
52 WEEK LOW
13.12
MARKET CAP
450.92M
P/E (TTM)
-3.1941
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
UroGen Pharma Reports Final Topline Results From OPTIMA II Phase 2b Trial Evaluating Efficacy, Safety Of UGN-102 For Intravesical Solution In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. (NASDAQ:URGN) today announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and safety of investigational UGN-102 (mitomycin) for intravesical
Benzinga · 6d ago
Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN) today announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and safety of investigational UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). As previously reported, 65% (41/63) of patients receiving UGN-102 achieved a complete response (CR) three months after the start of therapy. In this subset of patients, duration of response at nine months (12-months from start of therapy) was estimated by Kaplan-Meier analysis to be 72.5%. Median duration of response was not reached. The Company expects to initiate a Phase 3 study evaluating UGN-102 versus current standard of care by the end of the year.
Business Wire · 6d ago
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
UroGen Pharma Ltd. (NASDAQ:URGN) just released its quarterly report and things are looking bullish. Revenues and...
Simply Wall St. · 11/12 13:00
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGens Jelmyto® Effective January 1, 2021
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a permanent and product-specific J-code for Jelmyto® (mitomycin) for pyelocalyceal solution that will take effect on January 1, 2021. The J-code is expected to replace the previously issued temporary C-code and will standardize and facilitate reimbursement in the hospital outpatient, ambulatory surgery center and physician office settings of care beginning on January 1, 2021.
Business Wire · 11/11 13:00
Recap: UroGen Pharma Q3 Earnings
Shares of UroGen Pharma (NASDAQ:URGN) were unchanged after the company reported Q3 results.Quarterly Results Earnings per share were down 23.58% over the past year to ($1.31), which beat the estimate of ($1.49).Revenue of $3,461,000 up by 0.00% year over year, which beat the estimate of $3,340,000.Guidance UroGen Pharma hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Nov 09, 2020View more earnings on URGNTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/gh8p8meuRecent Stock Performance Company's 52-week high was at $35.2152-week low: $13.12Price action over last quarter: down 1.98%Company Profile UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. It has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The company's lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 9, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/09 13:33
UroGen Pharma Q3 EPS $(1.31) Beats $(1.49) Estimate, Sales $3.46M Beat $3.34M Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.49) by 12.08 percent. This is a 23.58 percent decrease over losses of $(1.06) per share from the
Benzinga · 11/09 13:16
UroGen Pharma EPS beats by $0.15, beats on revenue
UroGen Pharma (URGN): Q3 GAAP EPS of -$1.31 beats by $0.15.Revenue of $3.46M beats by $0.12M.Press Release
Seekingalpha · 11/09 13:01
UroGen Pharma Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 9, 2020 / UroGen Pharma Ltd.
ACCESSWIRE · 11/09 11:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of URGN. Analyze the recent business situations of Urogen Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average URGN stock price target is 43.00 with a high estimate of 59.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 18.62M
% Owned: 84.27%
Shares Outstanding: 22.09M
TypeInstitutionsShares
Increased
27
976.99K
New
10
-53.28K
Decreased
31
577.77K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
Arie Belldegrun
President/Chief Executive Officer/Director
Elizabeth Barrett
Chief Financial Officer/Chief Accounting Officer
Molly Henderson
Executive Vice President
Marina Konorty
Executive Vice President
Jim Ottinger
Chief Compliance Officer/General Counsel
Jason Smith
Other
Jeff Bova
Other
Polly Murphy
Other
Mark Schoenberg
Other
Elyse Seltzer
Independent Director
Cynthia Butitta
Independent Director
Fred Cohen
Independent Director
Kathryn Falberg
Independent Director
Stuart Holden
Independent Director
Ran Nussbaum
Independent Director
Shawn Tomasello
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Urogen Pharma Ltd stock information, including NASDAQ:URGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, URGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading URGN stock methods without spending real money on the virtual paper trading platform.